Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 3/23/22 → 2/14/25 |
Funding
- Anthos Therapeutics Incorporated: $123,772.00
A multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE
- Villano, PhD, John (PI)